<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7151825\results\search\drugs\results.xml">
  <result pre="of immunosuppression used in autoimmune conditions such as steroids and" exact="methotrexate" post="will also be discussed. •Discuss the implications of different"/>
  <result pre="blockers available. Human monoclonal antibodies, such as adalimumab, certolizumab, and" exact="golimumab" post="work by binding to TNF-alpha and preventing it from"/>
  <result pre="(PML) [6]. 3.6 Nonbiological drugs 3.6.1 Glucocorticoids Glucocorticoids such as" exact="prednisolone" post="or prednisone have been used for decades for their"/>
  <result pre="3.6 Nonbiological drugs 3.6.1 Glucocorticoids Glucocorticoids such as prednisolone or" exact="prednisone" post="have been used for decades for their anti-inflammatory properties."/>
  <result pre="understood. It is generally thought to be safe to continue" exact="methotrexate" post="during a mild, uncomplicated infection but it should be"/>
  <result pre="discussion with the patient's treating specialist. It is unclear whether" exact="methotrexate" post="is associated with an increased risk of particular infections"/>
  <result pre="•Patients taking short or low-dose steroid therapy (&amp;lt;20 mg/day of" exact="prednisolone" post="or equivalent) or inhaled or topical steroids •Patients taking"/>
  <result pre="prednisolone or equivalent) or inhaled or topical steroids •Patients taking" exact="methotrexate" post="at doses of ≤0.4 mg/kg/week or azathioprine at doses"/>
  <result pre="steroids •Patients taking methotrexate at doses of ≤0.4 mg/kg/week or" exact="azathioprine" post="at doses of ≤3 mg/kg/day •Travelers with autoimmune disease"/>
  <result pre="with the following [13] •High-dose corticosteroids—≥20 mg per day of" exact="prednisone" post="or equivalent when administered for ≥2 weeks •Alkylating agents"/>
  <result pre="agents (such as cyclophosphamide). •Antimetabolites (such as higher doses of" exact="methotrexate" post="or azathioprine). •Tumor necrosis factor (TNF) blockers. •Other biologic"/>
  <result pre="blockers. •Other biologic agents that are immunosuppressive or immunomodulatory, e.g.," exact="rituximab" post="or JAK inhibitors 4.3 General implications of significant immunosuppression"/>
  <result pre="of agent. For travel to South and South East Asia" exact="azithromycin" post="is a better choice due to the increased prevalence"/>
  <result pre="campylobacter strains. For patients on biological agents or JAK inhibitors" exact="azithromycin" post="would be a sensible choice of agent as it"/>
  <result pre="with other forms of immunosuppression, including a patient treated with" exact="rituximab" post="[73]. Chronic infection in immunosuppressed patients may rapidly progress"/>
  <result pre="treatment consists of reducing immunosuppression where possible and administration of" exact="ribavirin" post="[75]. A vaccine has been developed against HEV but"/>
  <result pre="case series showed that patients with inflammatory arthritis treated with" exact="infliximab" post="are at greater risk of developing symptomatic coccidioidomycosis than"/>
  <result pre="risk of developing symptomatic coccidioidomycosis than those not treated with" exact="infliximab" post="[94]. Most infections in immunocompetent hosts are either asymptomatic"/>
  <result pre="of diagnosis may be started on oral antifungal treatment, e.g.," exact="fluconazole" post="[92]. Immunosuppressed patients are at greater risk of severe"/>
  <result pre="J Med3588200881181718287603 73FraticelliP.BagnarelliP.TarantinoG.MartinoG.P.BenfaremoD.NobiliL.Chronic hepatitis E in a patient treated with" exact="rituximab" post="and mycophenolate mofetil for Sjogren's syndromeRheumatology551220162275227727498353 74HaagsmaE.B.van den BergA.P.PorteR.J.BenneC.A.VennemaH.ReimerinkJ.H.Chronic"/>
 </snippets>
</snippetsTree>
